Smith & Nephew SNATS Inc Stock News

London stocks rebounded from earlier weakness as energy names charged ahead, while Smith & Nephew shares surged on results.

Smith & Nephew (SNN) appointed Deepak Nath as CEO, effective April 1, succeeding Roland Diggelmann, who will step down by mutual agreement on March 31.Nath joins Smith+Nephew from

Smith & Nephew (SNN) board recommended a final dividend of 23.1¢ per share (46.2¢ per ADS). The company said that together with the Interim Dividend of 14.4¢ per share (28.8¢ per ADS).

Smith & Nephew press release (SNN): FY Adjusted EPS $0.809 (+25% Y/Y)Revenue of $5.21B (+14.3% Y/Y) misses by $10M.Operating profit $593M (+101% Y/Y).Outlook:For 2022 the company

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q4 2021 Results - Earnings Call Transcript

(Reuters) Smith+Nephew named Siemens Healthineers executive Deepak Nath as its new boss on Tuesday after the medical products maker narrowly missed analysts estimate for annual profit, weighed down by supply issues and the pandemic.

Smith & Nephew PLC (LSE:SN) said pre-tax profit more than doubled in 2021, helped by strong sales in its sports medicine & ENT and wound care segments, all of which delivered revenue higher than in 

DUBLIN--(BUSINESS WIRE)--The "Global Surgical Robots Market" report has been added to ResearchAndMarkets.com''s offering. The global surgical robots market was valued at $8052.67 Million in the year 2020 with North America region leading the regional market share. Companies Mentioned Intuitive Surgical Stryker Corporation Medtronic Smith & Nephew Zimmer Biomet Accuray Incorporated Renishaw Asensus Surgical Medrobotics Corporation Think Surgical The market is projected to display momentous gr

HSBC, Anglo American were in the lead in London on Monday, while housing stocks were also in focus.

Smith+Nephew's (SNN) acquisition of Engage Surgical reinforces its growth strategy while expanding its Orthopaedic Reconstruction product line.

Smith+Nephew's (SNN) acquisition of Engage Surgical reinforces its growth strategy while expanding its Orthopaedic Reconstruction product line.

Medical devices manufacturer continues to suffer from lower demand than pre-pandemic, but recovery is in progress. The company has set out a growth plan but I don't find it persuasive.